Skip to main content

Table 1 Demography and severity of illness data

From: The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study

  Controls ECMO
No RRT RRT No RRT RRT
(n = 5) (n = 5) (n = 6) (n = 5)
Male/Female 3/2 3/2 1/5 3/2
Age (years) 55.0 (48–61) 56 (46–66) 29 (16–46) 38 (23–56)
Total body weight (kg) 80 (75–85) 70 (60–100) 69 (60–80) 70 (70–76)
Mechanical ventilation 5/5 5/5 5/5 5/5
Type of ECMO (VA/VV) 0/0 0/0 3/3 2/3
Day 1 SOFA score 3 (3–4) 15 (14–16) 9 (7–14) 16 (13–17)
Plasma creatinine concentration (μmol/L) 73 (55–101) na* 75 (44–82) na*
Creatinine clearance (mL/min) 106 (98–127) na* 108 (65–183) na*
RRT mode - CVVH - EDD-f
Serum bilirubin (μmol/L) 9 (5–23) 93 (36–115) 23 (9–73) 58 (34–134)
Serum albumin (g/L) 22 (18–36) 26 (23–36) 31 (27–35) 24 (22–32)
Serum proteins (g/L) 56 (55–70) 62 (60–65) 49 (46–54) 44 (34–56)
Meropenem daily dose (g) 1 q 8 h 1 q 8 h 1 q 8 h 1q 8 h
Plasma C max (mg/L) 93 (74–119) 58 (52–68) 42 (27–56) 59 (50–86)
Plasma C min (mg/L) 0 (0–2) 7.5 (5–18) 4.9 (2–10) 18 (7–43)
  1. *Patients RRT dependent. The biochemical indices were measured on day of pharmacokinetic sampling. Data are presented as median (IQR). ECMO, extracorporeal membrane oxygenation; RRT, renal replacement therapy; VA, venoarterial; VV, venovenous; SOFA, sequential organ failure assessment; CVVH, continuous venovenous haemofiltration; EDD-f, extended daily diafiltration.